In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

• Published in: Nature communications Vol. 12; no. 1; p. 3055
• Main Authors: Dai, Meiou, Yan, Gang, Wang, Ni, Daliah, Girija, Edick, Ashlin M., Poulet, Sophie, Boudreault, Julien, Ali, Suhad, Burgos, Sergio A., Lebrun, Jean-Jacques
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.05.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 13/109; 13/2; 13/31; 13/51; 13/95; 14/63; 38/43; 42/47; 45/23; 45/41; 631/67/1347; 64/60; 692/4028/67/69; 96/1; 96/106; 96/2; Apoptosis; Breast cancer; Combination therapy; CRISPR; Genomes; Humanities and Social Sciences; In vivo methods and tests; Medical innovations; multidisciplinary; Pharmacology; Science; Science (multidisciplinary); TOR protein; Tumor suppressor genes; Tumorigenesis; Tumors; Xenografts; Xenotransplantation; Yes-associated protein

Triple negative breast cancer (TNBC) patients exhibit poor survival outcomes and lack effective targeted therapies. Using unbiased in vivo genome-wide CRISPR screening, we interrogated cancer vulnerabilities in TNBC and identified an interplay between oncogenic and tumor suppressor pathways. This st...